Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Drug Hypersensitivity, DRESS Syndrome. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Origin and Function of Eosinophilic Polynuclear During Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
Overview
Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic Symptoms" is a serious drug allergy which can be life-threatening for patients with serious organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no study has focused on the characterization of eosinophils, while paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils and few data are available concerning immune polarization of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on increase activation markers membrane expression of cutaneous eosinophils suggest that this approach could allow the identification of endotypes in which eosinophils are involved and contribute to organ damages. The correlation between tissue infiltration of eosinophils and their degree of activation would then justify the development of targeted therapeutic strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of circulating and cutaneous eosinophils in patients with DRESS compared with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of this eosinophilia.
Primary outcome measures
- Activation status of circulating eosinophils by flow cytometry [Time frame: Baseline]
Secondary outcome measures (7)
- Mean fluorescence intensity of CCR3 and IL-5R markers [Time frame: Baseline]
- Percentage of Th2 polarized T cells [Time frame: Baseline]
- Percentage of ILC2 [Time frame: Baseline]
- Serum levels (ELISA) of inflammatory markers [Time frame: Baseline]
- Correlation between the number of activated circulating eosinophils, area degranulation and severity of DRESS [Time frame: Baseline]
- Density of extracellular granules (degranulation area and number / mm2) on skin biopsies [Time frame: Baseline]
- NGS analysis of rearrangements of TCR (T cell receptor) [Time frame: Baseline and 3 months]
Eligibility criteria
Inclusion criteria
Group 1 (DRESS): adult with a diagnosis of DRESS based on the following four criteria:
- Cutaneous rash occurring at least 24 hours and at most 2 months after continuous medication use
- Fever over 38 degre celcius
- At least one organ dysfunction among:
- Lymphadenopathy
- hepatitis
- Pulmonary involvement
- Cardiac involvement: myocarditis, pericarditis
- Renal impairment
- At least one of the following hematological anomalies:
- Eosinophilia ≥ 500 / mm3 .
- RegiSCAR Score ≥ 4
Groups 2 and 3 (Drug induced maculopapular exanthema without or with eosinophilia).
- Adult with drug-induced rash
- Without clinical criteria of severity defined by Djien among :
- An evolution of more than 21 days
- with organ damage as defined in group 1
Group 2 (MPE without eosinophilia): blood eosinophils < 500 / mm3
Group 3 (MPE with eosinophilia): blood eosinophils ≥ 500 / mm3
Exclusion criteria
- Other cause of eosinophilia including cancer, blood disease before the introduction of suspected molecule(s).
- On going oral or local corticosteroid therapy, anti-leukotriene therapy (MONTELUKAST) by the month preceding the study;
- Anti-IgE therapy (OMALIZUMAB, LIGELIZUMAB), anti-IL-5 therapy (MEPOLIZUMAB, BENRALIZUMAB) or anti-IL4 and / or anti-IL13 therapy (DUPILUMAB, TRALOKINUMAB) in the 6 months preceding the study.
- Any pregnant or lactating woman.
- Contraindication related to the blood volume taken for the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
France · 11 centers
- CH d'Arras — Arras
- CH de Boulogne — Boulogne-sur-Mer
- Assistance Publique - Hôpitaux de Paris - HENRI MONDOR — Créteil
- CH de Douai — Douai
- CH de Dunkerque — Dunkirk
- CH LENS — Lens
- Hop Claude Huriez Chr Lille — Lille
- Groupe Hospitalier de l'Institut Catholique de Lille — Lille
- … and 3 more centers
Identifiers
NCT: NCT04330118 · 2019_01 · 2019-A02026-51